BiotechTube

ASP2151 + Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Herpes Genitalis

Conditions

Herpes Genitalis, Herpes Zoster

Trial Timeline

Sep 1, 2005 → Dec 1, 2005

NCT ID
NCT02852876

About ASP2151 + Placebo

ASP2151 + Placebo is a phase 1 stage product being developed by Astellas Pharma for Herpes Genitalis. The current trial status is completed. This product is registered under clinical trial identifier NCT02852876. Target conditions include Herpes Genitalis, Herpes Zoster.

What happened to similar drugs?

8 of 20 similar drugs in Herpes Genitalis were approved

Approved (8) Terminated (1) Active (11)
✅Zoster Vaccine, Live + Comparator: placeboMerckApproved
✅Zoster Vaccine LiveMerckApproved
✅ZOSTAVAX®MerckApproved
✅FamciclovirNovartisApproved
✅Famciclovir + PlaceboNovartisApproved
✅FamciclovirNovartisApproved
✅FamciclovirNovartisApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02796118Phase 1Completed
NCT02852876Phase 1Completed

Competing Products

20 competing products in Herpes Genitalis

See all competitors
ProductCompanyStageHype Score
mRNA-1608ModernaPhase 2
0
mRNA-1468ModernaPhase 2
0
ASP2151 + Valacyclovir hydrochlorideAstellas PharmaPhase 2
35
ASP2151 + valacyclovir + PlaceboAstellas PharmaPhase 2
35
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
GSK1349572 + EfavirenzShionogiPhase 1
29
Zoster Vaccine, Live + Comparator: PlaceboMerckPhase 2
35
Comparator: V212 + Comparator: PlaceboMerckPhase 1
29
Zoster Vaccine, LiveMerckPhase 3
40
V212 + PlaceboMerckPhase 3
40
zoster vaccine live (ZOSTAVAX™) + Comparator: PlaceboMerckPhase 3
40
ZOSTAVAXMerckPhase 3
40
Zoster Vaccine, Live (AMP) + Zoster Vaccine, LiveMerckPhase 3
40
V212 + PlaceboMerckPhase 2
35
V212 + Matching placeboMerckPhase 3
40
V212 Lot 1 + V212 Lot 2 + V212 Lot 3MerckPhase 3
32
HSV 2 Formulation 1 + HSV 2 Formulation 2 + HSV 2 Formulation 3 + HSV 2 Formulation 4 + HSV 2 Formulation 5 + HSV 2 Formulation 6 + Sodium Chloride 0.9%MerckPhase 1
21
V212 + PlaceboMerckPhase 1
29
Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ + Comparator: placebo (concomitant-vaccine matched) + Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23MerckPhase 3
40
ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal + ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal + Full Dose Intradermal Placebo + Intradermal PlaceboMerckPhase 1
29